SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (653)5/5/2004 3:56:34 PM
From: Biomaven  Read Replies (2) | Respond to of 897
 
Tuck,

I agree that the ARDM results do pose a challenge to NKTR, and so the NKTR project certainly has got to be looked at as riskier than it was previously. But if it turns out they don't have the same issue then the stock should benefit from ARDM's problem.

I haven't followed NKTR in quite a while, so I've forgotten the details of their trial. Was it also Type I's exclusively?

Peter



To: tuck who wrote (653)5/5/2004 3:57:40 PM
From: tuck  Respond to of 897
 
Starting here with a half position of ONXX again, 200 shares at $55.70.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News